SP500+0.16%
NASDAQ+0.65%
DOW-0.30%
VIX-2.21%
RUSSEL+0.00%
SP500+0.16%
NASDAQ+0.65%
DOW-0.30%
VIX-2.21%
RUSSEL+0.00%
SP500+0.16%
NASDAQ+0.65%
DOW-0.30%
VIX-2.21%
RUSSEL+0.00%

LRCX

NEGATIVE BIAS

Lam Research Corporation · Technology

$264.62+2.27%LAST CLOSE
24H+2.27%
1W+21.14%
1M+20.91%
1Y+342.43%
Live Chart · LRCX
1DNY TIME

BOGA AI Daily Brief

"LRCX shows a "SELL" signal with 52% confidence. Today's 9.87% surge brings it within 1.1% of its 52-week high, yet RVOL is only 0.74x. While the EMA stack is bullish, ADX is low at 18.3. RSI at 61.3 suggests it is approaching overbought levels. The P/E ratio of 50.51 is significantly higher than the sector median of 32.77. While revenue growth is strong at 22.1%, the high valuation relative to peers suggests potential downside. Watch for earnings release on April 22nd; any miss will likely trigger a sell-off."

Confidence

54%

Sentiment

Bullish

Share Analysis

BOGA Master Score

54.0

High conviction score

BOGA AI Model Projection

Strategic Observation Zone$221.53 - $265.94
Projected Growth Objective$295.49 - $316.60
Model Invalidation Level$228.02 - $240.02
Risk/Reward1.5:1
AD-S2 · 300×250 Sidebar

Technical Indicators

RSI (14)

67.2

Neutral

MACD

4.907

NEUTRAL

RVOL

0.66x

Normal

Trends

UP

UP

EMA Stack

Bullish

STABLE

BB Squeeze

LOW

MONITOR

Fundamentals & Margins

Market Cap

$0.33T

P/E Ratio

vs Sector: 39.216118

54.467075

FCF Yield

1.5%

Gross Margin

49.8%

Operating Margin

33.9%

Net Margin

30.2%

Sector Context

Benchmarked against

XLK

5D Performance

+4.53%

LRCX is currently ranked in the top 20% of its sector based on BOGA Master Scores. It has outperformed XLK by 4.2% over the last 30 trading days.

Insider Activity (90D)

TransactionSharesNet Direction
Buys0SELL
Sells5

Last Transaction: SELL 4571 shares

Score Categories

Share This Insight

Help others discover this score. Professional analysts share high-conviction data.

Share This Insight

Help others discover this score. Professional analysts share high-conviction data.

Recent Analysis & News